For the fourth consecutive year, physicians ranked Pfizer reps as the pharmaceutical sales division that provides the most value to their practices.
According to Scott-Levin's annual survey, "Sales Force Structures & Strategies, 1998-1999," general and family practitioners, cardiologists, general surgeons and psychiatrists rated Pfizer above competitors. And, among the nine core specialty groups included in the survey, Pfizer came out on top.
Several factors helped tip the scales in Pfizer's favor in 1998, according the Newtown, PA-based consulting firm.
For one, the company launched Viagra for erectile dysfunction, a product that garnered widespread media and consumer interest. Physicians' need for information about the heavily requested drug effectively opened the door to sales reps with answers to their questions. Second, the company added Alta, its fifth sales force, for an additional 650 bodies in the field. The Alta force targeted primary care physicians.
Pfizer also launched Lipitor, a cholesterol reducer that the company copromotes with Parke-Davis, and developed a direct-to-consumer advertising campaign for Aricept, a product indicated for the treatment of Alzheimer's disease.
However, other sales forces earned the respect of certain customers, too.
Merck, for example, was rated number one by internal medicine specialists, nephrologists and endocrinologists. Glaxo Wellcome was rated best by pulmonologists and neurologists.
Wyeth-Ayerst, meanwhile, scored well with OB/GYNs and orthopedic surgeons, and Schering-Plough earned the nod from allergists and otorhinolaryngologists.
Gastroenterologists cited Astra Merck as their favorite, and pediatricians named Ross as their top pick in terms of salespeople. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.